Cargando…
Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma
Nivolumab is an active treatment in patients with metastatic melanoma. We report a case of a patient with metastatic malignant melanoma who was given nivolumab as an advanced-line treatment. She received nivolumab 3 mg/kg every 2 weeks for 4 cycles and developed aplastic anemia. To the best of our k...
Autores principales: | Rouvinov, Keren, Nalbandyan, Karen, Kozlov, Victor, Peled, Nir, Yakobson, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381922/ https://www.ncbi.nlm.nih.gov/pubmed/30792642 http://dx.doi.org/10.1159/000495980 |
Ejemplares similares
-
Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report
por: Meyers, D. E., et al.
Publicado: (2018) -
Programmed death-ligand 1 expression discrepancy between primary tumor and metastatic lymph nodes in non-small cell lung cancer
por: Kian, Waleed, et al.
Publicado: (2020) -
Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
por: Shalata, Walid, et al.
Publicado: (2023) -
Aplastic anemia and membranous nephropathy induced by intravenous mercury
por: Priya, N., et al.
Publicado: (2012) -
Radiotherapy-Induced Atrial Myxoma: A Case Report and Literature Review
por: Shalata, Walid, et al.
Publicado: (2023)